Thermo Fisher Scientific enrolls first patient in new registry, marking launch of its PPD™ CorEvitas™ Obesity Registry

Thermo Fisher Scientific has announced the launch of their new obesity registry designed to generate long-term real-world evidence on the effectiveness, safety, and patient experience of obesity management therapies in routine clinical practice. 

The newly established PPD™ CorEvitas™ Obesity Registry is a prospective, observational initiative that will follow patients longitudinally in routine clinical practice. It is designed to collect structured real-world data (RWD) from both clinicians and patients on obesity management therapies – including anti-obesity medicines – capturing treatment use, outcomes, and patient experience across a range of care settings. 

The launch follows Thermo Fisher’s recent announcement of an international Alzheimer’s disease registry, which similarly aims to strengthen RWE generation for long-term disease management, reflecting a broader strategy to build disease-specific registries that capture outcomes beyond controlled clinical trials. 

Obesity is a chronic, complex disease associated with significant clinical and economic burden. It is linked to serious comorbidities, including type 2 diabetes and cardiovascular disease, and can substantially affect quality of life. More than 100 million adults in the US are living with obesity, including over 22 million with severe obesity, while globally the economic impact of overweight and obesity is projected to reach approximately $3 trillion annually by 2030. 

Against this background, the CorEvitas Obesity Registry is intended to address evidence gaps by capturing how obesity treatments are used and experienced in routine practice. The registry is designed to collect detailed clinician-reported and patient-reported data, enabling the assessment of disease progression, treatment patterns, adherence, satisfaction, and clinical outcomes, including anthropometric measures. By incorporating both clinical and patient perspectives, the initiative aims to provide a more comprehensive understanding of real-world treatment pathways and challenges encountered throughout the care journey. As Leslie Harrold (Vice President and Global Head of Real-World Science and Strategy, PPD CorEvitas Clinical Registries, Thermo Fisher Scientific) explained: 

“The CorEvitas Obesity Registry represents a major step forward in understanding the use and outcomes associated with obesity treatments in everyday clinical practice. Insights generated from this robust, real-world evidence base will inform the healthcare community on treatment effectiveness, safety and the patient experience associated with obesity care, which will advance care for millions living with the condition.” 

The obesity registry is the 15th independent registry within the PPD™ CorEvitas™ Clinical Registries portfolio, part of Thermo Fisher Scientific’s PPD clinical research business. CorEvitas registries comprise structured, regulatory-grade clinical data from more than 500 investigator sites and longitudinal follow-up on over 100,000 patients, and the independent registry model has been accepted by regulators for long-term post-authorization safety studies across multiple therapeutic areas, supporting the generation of RWE alongside clinical trial data.